CoChat

P11 promoter methylation predicts the antidepressant effect of electroconvulsive therapy

Open access
Neyazi, Alexandra, Theilmann, Wiebke, Brandt, Claudia, Rantamäki, Tomi, Matsui, Nobuaki, Rhein, Mathias, Kornhuber, Johannes, Bajbouj, Malek, Sperling, Wolfgang, Bleich, Stefan, Frieling, Helge, Löscher, Wolfgang · 2018 · Translational Psychiatry
Cited by 45

The DOI matches its Crossref record; 17 of the 17 references it cites were found in a registry or an index.

Abstract

Although electroconvulsive therapy (ECT) is among the most effective treatment options for pharmacoresistant major depressive disorder (MDD), some patients still remain refractory to standard ECT practise. Thus, there is a need for markers reliably predicting ECT non/response. In our study, we have taken a novel translational approach for discovering potential biomarkers for the prediction of ECT response. Our hypothesis was that the promoter methylation of p11, a multifunctional protein involved in both depressive-like states and antidepressant treatment responses, is differently regulated in ECT responders vs. nonresponders and thus be a putative biomarker of ECT response. The chronic mild stress model of MDD was adapted with the aim to obtain rats that are resistant to conventional antidepressant drugs (citalopram). Subsequently, electroconvulsive stimulation (ECS) was used to select responders and nonresponders, and compare p11 expression and promoter methylation. In the rat experiments we found that the gene promoter methylation and expression of p11 significantly correlate with the antidepressant effect of ECS. Next, we investigated the predictive properties of p11 promoter methylation in two clinical cohorts of patients with pharmacoresistant MDD. In a proof-of-concept clinical trial in 11 patients with refractory MDD, higher p11 promoter methylation was found in responders to ECT. This finding was replicated in an independent sample of 65 patients with pharmacoresistant MDD. This translational study successfully validated the first biomarker reliably predicting the responsiveness to ECT. Prescreening of this biomarker could help to identify patients eligible for first-line ECT treatment and also help to develop novel antidepressant treatment procedures for depressed patients resistant to all currently approved antidepressant treatments.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1038/s41398-017-0077-3

Cites

17 of 17 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 17 references

Cited by

See all 45

Metadata

Authors
Neyazi, A., Theilmann, W., Brandt, C., Rantamäki, T., Matsui, N., Rhein, M., Kornhuber, J., Bajbouj, M., Sperling, W., Bleich, S., Frieling, H., & Löscher, W.
Venue
Translational Psychiatry
Published
2018-01-22
Volume
8
Issue
1
Pages
25-25
ISSN
2158-3188 (ISSN-L)
OpenAlex
W2806046698
Cited by
45
References
17
FWCI
3.47
Type
journal article
Language
en
Open access
gold

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: P11 promoter methylation predicts the antidepressant effect of electroconvulsive therapy. https://app.cochat.ai/papers/10.1038/s41398-017-0077-3
The paper
Neyazi, A., Theilmann, W., Brandt, C., Rantamäki, T., Matsui, N., Rhein, M., Kornhuber, J., Bajbouj, M., Sperling, W., Bleich, S., Frieling, H., & Löscher, W. (2018). P11 promoter methylation predicts the antidepressant effect of electroconvulsive therapy. Translational Psychiatry. https://doi.org/10.1038/s41398-017-0077-3

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.